Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C7H7ClN2O4S
CAS Number:
Molecular Weight:
250.66
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Product Name
Furosemide Related Compound B, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C7H7ClN2O4S/c8-4-2-5(9)3(7(11)12)1-6(4)15(10,13)14/h1-2H,9H2,(H,11,12)(H2,10,13,14)
SMILES string
Nc1cc(Cl)c(cc1C(O)=O)S(N)(=O)=O
InChI key
QQLJBZFXGDHSRU-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
furosemide
manufacturer/tradename
USP
mp
267 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Looking for similar products? Visit Product Comparison Guide
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Furosemide Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
G M Hanna et al.
Journal of AOAC International, 76(3), 526-530 (1993-05-01)
A simple, specific, and accurate proton nuclear magnetic resonance (1H-NMR) spectroscopic method has been developed for the identification and assay of furosemide and its degradation product, 4-chloro-5-sulfamoylanthranilic acid (CSA), in tablets and injections. Dissolution of the sample in D2O-NaOD resulted
D E Smith et al.
Drug metabolism and disposition: the biological fate of chemicals, 8(5), 337-342 (1980-09-01)
The objectives of this study were to qualitatively and quantitatively compare the metabolism, pharmacokinetics, and bioavailability of furosemide in healthy volunteers after intravenous and oral administration. We also determined the plasma protein binding of furosemide in vivo after iv administration.
[Determination of furosemide and its metabolic products in plasma and urine by high performance liquid chromatography and clinical application].
Y Miwa et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 108(11), 1087-1092 (1988-11-01)
L Z Benet et al.
Federation proceedings, 42(6), 1695-1698 (1983-04-01)
A variety of furosemide assays and their application to biological samples have been described over the past 2 decades. We describe development of a specific, sensitive assay appropriate for efficient measurement of large numbers of biological samples. With development of
H Nakahama et al.
European journal of clinical pharmacology, 32(3), 313-315 (1987-01-01)
Urine from 5 renal transplant recipients treated with frusemide was analyzed for unchanged frusemide (F), glucuronidated frusemide (G) and 4-chloro-5-sulfamoylanthranilic acid (CSA) by HPLC. In 3 recipients, whose renal function recovered steadily and whose hepatic function was normal throughout, the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service